Table 1. . Base line characteristics of patients.

	Primary site of tumor	Age (years)/sex	Mutation	Response to imatinib	Response to sunitinib	Response to regorafenib	Other treatments tried	Sites of metastasis
A	Jejunum	28/male	c-KIT exon 17	PR	PD	PD	Progressed on immunotherapy	Liver, omental, serosa
B	Duodenum	49/male	c-KIT exon 11	PR	PD	PD	Progressed on immunotherapy	Liver, omental, serosa, bone, nodes
C	Stomach	40/male	c-KIT exon 9	PR	PD	PR		Liver, omental, bone
D	Duodenum	60/female	Not known	PR	PD	PD	Progressed on pazopanib	Liver, omental, serosa
E	Stomach	76/male	PDGFRA D842V	PD	Could not tolerate	PR		Liver, serosa

PD: Progressive disease; PDGFRA: Platelet-derived growth factor alpha; PR: Partial response; SD: Stable disease.